Chimeric Therapeutics Ltd (ASX:CHM) has appointed Dr Eliot Bourk as its vice president, Business and Corporate Development to drive the growth of its cancer therapy pipeline by advancing strategic business opportunities, initiatives and partnerships.
Dr Bourk will lead business and corporate development, with a near-term focus on Chimeric Therapeutics additional novel cell therapies.
Critical to long-term success
Chimeric executive chairman Paul Hopper said: “We‘re very fortunate to have Dr Bourk joining us.
“His background in cell therapy development will be critical to advancing Chimeric’s growth with new and novel cell therapy assets, optimised for commercialisation.
“His extensive cell therapy experience further complements the cell therapy expertise of our leadership team that we believe is critical to our long-term success in cell therapy.”
Dr Bourk’s expertise
Dr Bourk joins Chimeric from Kite Pharmaceuticals, where he led early commercial strategy, responsible for the optimisation of a portfolio of early-stage cell therapy pipeline assets and for guiding business development strategies and transactions.
In this role, Dr Bourk guided product development decisions to maximise future commercial opportunity, led the development of corporate disease strategies for solid tumours and haematological malignancies and partnered with translational research teams to focus research and development efforts.
He was also instrumental in defining the business development priorities for solid tumours and haematological malignancies, building academic and industry partnerships to identify opportunities and leading commercial diligence for all transactions.
Prior to joining Kite, Dr Bourk was a founding member of the cell therapy commercial team at Celgene Corporation.
At Celgene, Dr Bourk was the commercial lead for the development of next-generation CAR T platforms, working in partnership with research, development and technical operations to provide commercial insight to guide development and investment in next-generation technologies.
The company is a clinical-stage cell therapy company focused on bringing the promise of cell therapy to life for patients with cancer.
Chimeric Therapeutics is in a Phase 1 clinical trial for its lead asset, CLTX-CAR T, a novel and promising CAR T therapy for the treatment of patients with glioblastoma (GBM).
Developed by scientists at the City of Hope Medical Centre in California, CLTX-CAR T technology incorporates chlorotoxin (CLTX), a peptide derived from scorpion toxin, as a novel CAR tumor recognition domain.
Chimeric Therapeutics is now actively engaged in further developing its oncology pipeline with new and novel cell therapy assets.